Titan gets the nod from USPTO

|About: Titan Pharmaceuticals,... (TTNP)|By:, SA News Editor

The USPTO sends a Notice of Allowance to Titan Pharmaceuticals (TTNP +3.9%) for a patent covering the sustained release of dopamine using the company's proprietary long-term drug delivery technology, ProNeura. "Implantable Polymeric Device for Sustained Release of a Dopamine Agonist" provides IP protection for Titan's ProNeura program for Parkinson's disease and carries a term to at least 2024.